Research programme: CTLA4-Ig fusion proteins - Perseid Therapeutics

Drug Profile

Research programme: CTLA4-Ig fusion proteins - Perseid Therapeutics

Alternative Names: MAXY-12; MAXY-4; MAXY-740

Latest Information Update: 23 May 2011

Price : $50

At a glance

  • Originator Maxygen
  • Developer Perseid Therapeutics
  • Class Immunoglobulin fusion proteins
  • Mechanism of Action CD28 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Autoimmune disorders; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 17 May 2011 Perseid Therapeutics has been acquired by Astellas Pharma
  • 01 Feb 2011 A lead candidate, ASP 2408, enters into clinical development in the US
  • 25 Jan 2010 Preclinical development is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top